Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase

European Annals of Allergy and Clinical Immunology

Volumn 38, Issue 9, 2006, Pages 310-312

  Giordano, T ^a   Quarta, C ^a   Bruno, M E ^b   Falagiani, P ^b   Riva, G ^b  

^a VITO FAZZI HOSPITAL   (Italy)

^b Lofarma SpA   (Italy)

Author keywords

Asthma; Build up phase; Rhinitis; Sublingual immunotherapy

Indexed keywords

ALLERGOID; CETIRIZINE; FLUTICASONE; IMMUNOLOGIC AGENT; PREDNISONE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FATIGUE; FEMALE; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; MALE; RHINITIS; SOMNOLENCE;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CATS; CHILD; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAIR; HUMANS; MALE; MIDDLE AGED; OLEA; PARIETARIA; PLANT EXTRACTS; POACEAE; POLLEN; PYROGLYPHIDAE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845927948     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Passalacqua G., Albano M., Fregonese L., Riccio A., Pronzato C., Mela G.-S., Canonica G.-W. - Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. The Lancet 1998;351:629-32.
2. Lombardi C., Gargioni S., Melchiorre A., Tiri A., Falagiani P., Canonica G.-W., Passalacqua G. - Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001;56:989-992.
3. Di Rienzo V., Pagani A., Parmiani S., Passalaqua G., Canonica G.-W. - Post- marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999;54:1110-1113.
4. Rossi R.-E., Monasterolo G. - Safety of ultra-rush (two hours) sublingual-swallow immunotherapy in allergic patients. Giorn It Allergol Immunol Clin 2002;12:221-226.
5. Grosclaude M., Bouillot P., Alt R., Leynadier F., Scheinmann P., Ruffin P., Basset D., Fadel R., Andre C. - Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol. 2002;129:248-253.
6. Passalacqua G., Lombardi C., Guerra L., Compalati E., Fumagalli F., Canonica G.-W. - Sublingual immunotherapy: no more doubts. Eur Ann Allergy Clin Immunol 2005;37: 314-320.
7. Mistrello G., Brenna O., Roncarolo D., Zanoni D., Gentili M., Falagiani P. - Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996;51:8-15.
8. Rossi R.-E., Monasterolo G. - A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. International Journal of Immunopathol and Pharmacol 2005;18:277-285.
9. Gammeri E., Arena A., D'Anneo R., La Grutta S. - Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol et Immunopathol 2005;33(3):142-4.
10. Tripodi S., Di Rienzo Businco A., Benincori N., Scala G., Pingitore G. - Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2006;139:149-152.